Compare LFMD & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | PLYX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | 384 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 271.8M |
| IPO Year | N/A | N/A |
| Metric | LFMD | PLYX |
|---|---|---|
| Price | $4.76 | $3.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $9.14 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.3M | 106.6K |
| Earning Date | 05-06-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.52 | N/A |
| Revenue Next Year | $18.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $2.20 |
| 52 Week High | $15.34 | $9.18 |
| Indicator | LFMD | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 34.57 |
| Support Level | $3.39 | $2.58 |
| Resistance Level | $4.93 | $7.29 |
| Average True Range (ATR) | 0.36 | 0.57 |
| MACD | -0.00 | -0.21 |
| Stochastic Oscillator | 47.16 | 21.70 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.